Sugi Predict

Sugi Predict / Compounds / SCHEMBL9715527

SCHEMBL9715527

SCHEMBL9715527

COc1ccc(COCCC=O)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ CA1 P00915 1/20 0.49
▸ CA2 P00918 1/20 0.49
▸ IDO1 P14902 3/20 0.48
▸ AGXT P21549 2/20 0.48
▸ NPC1 O15118 2/20 0.45
▸ RAB9A P51151 2/20 0.45
▸ APP P05067 7/20 0.45
▸ LTA4H P09960 1/20 0.44
▸ HTT P42858 1/20 0.43
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ TP53 P04637 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ ALOX12 P18054 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ CYP2A6 P11509 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041109 0.94 L3MBTL1 (0.52) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL28420417 0.88 L3MBTL1 (0.57) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL12444883 0.87 L3MBTL1 (0.60) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL16919290 0.83 IDO1 (0.47) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL8499580 0.82 IDO1 (0.61) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL18031455 0.82 ALDH1A1 (0.56) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL3961229 0.81 IDO1 (0.52) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL2556007 0.81 IDO1 (0.45) TDP1L3MBTL1CA1CA2IDO1
SCHEMBL2556009 0.81 IDO1 (0.45) TDP1L3MBTL1CA1CA2IDO1
Formic Acid SCHEMBL6366129 0.79 IDO1 (0.53) TDP1L3MBTL1CA1CA2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250243219-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CYPRALIS LIMITED (GB) 2025-07-31 — — US disclosed
EP-4526308-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF Cypralis Limited (GB) 2025-03-26 — — EP disclosed
CN-119451968-A Macrocyclic compounds and uses thereof 西普拉里斯有限公司 2025-02-14 — — CN disclosed
US-20250051302-A1 Method for Preparation of (2R,3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol Derivatives DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2025-02-13 — — US disclosed
CN-118401509-A Process for preparing (2R, 3S) -2- (benzo [ d ] imidazolylpiperidin-3-ol derivatives 株式会社大熊制药 2024-07-26 — — CN disclosed
US-20240165259-A1 BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-05-23 — — US disclosed
EP-4320073-A1 BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS Dana-Farber Cancer Institute, Inc. (US) 2024-02-14 — — EP disclosed
CN-117337267-A Bioorthogonal reactions suitable for click/click cancellation applications 达纳－法伯癌症研究所公司 2024-01-02 — — CN disclosed
WO-2023223057-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CYPRALIS LIMITED (GB) 2023-11-23 — — WO disclosed
US-20230212187-A1 FUSED RING DERIVATIVES AND USE THEREOF IN PHARMACY CISEN PHARMACEUTICAL CO., LTD (CN) 2023-07-06 — — US disclosed
US-8329742-B2 Macrocyclic compounds useful as pharmaceuticals EISAI CO., LTD. (JP) 2012-12-11 — — US disclosed
US-8329742-B2 Macrocyclic compounds useful as pharmaceuticals EISAI CO., LTD. (JP) 2012-12-11 — — US disclosed
US-20110144101-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI CO., LTD. (JP) 2011-06-16 — — US disclosed
US-20110144101-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS EISAI CO., LTD. (JP) 2011-06-16 — — US disclosed
US-7915306-B2 For therapy of inflammatory or autoimmune disorders EISAI CO., LTD. (JP) 2011-03-29 — — US disclosed
US-7915306-B2 For therapy of inflammatory or autoimmune disorders EISAI CO., LTD. (JP) 2011-03-29 — — US disclosed
US-7799827-B2 Macrocyclic compounds useful as pharmaceuticals EISAI CO., LTD. (JP) 2010-09-21 — — US disclosed
US-7799827-B2 Macrocyclic compounds useful as pharmaceuticals EISAI CO., LTD. (JP) 2010-09-21 — — US disclosed
EP-1944307-A2 Synthetic Salicylihalamides, Apicularens and Derivatives Thereof Board of Regents, The University of Texas System (US) 2008-07-16 — — EP disclosed
US-5126437-A ALDOPHOSPHAMIDE GLYCOSIDES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICAL ACTIVE COMPOUNDS BAYER AKTIENGESELLSCHAFT (DE) 1992-06-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110144101-A1 MACROCYCLIC COMPOUNDS USEFUL AS PHARMACEUTICALS FLT1, TBXA2R, VEGFA TDP1 1555/4885L3MBTL1 3648/4885CA1 3596/4885
US-20250051302-A1 Method for Preparation of (2R,3S)-2-(benzo[d]imidazolylpropyl)piperidin-3-ol Derivatives PIR, CBR3, UBE2D3 TDP1 4292/4885L3MBTL1 4777/4885CA1 4818/4885
US-20230212187-A1 FUSED RING DERIVATIVES AND USE THEREOF IN PHARMACY ABCB1, CYP3A43, CYP3A7 TDP1 4168/4885L3MBTL1 4881/4885CA1 4584/4885
US-20240165259-A1 BIOORTHOGONAL REACTION SUITABLE FOR CLICK/UNCLICK APPLICATIONS CILK1, SYMPK, DCK TDP1 3667/4885L3MBTL1 3251/4885CA1 3606/4885
US-20250243219-A1 MACROCYCLIC COMPOUNDS AND USES THEREOF CASP3, TNNC1, BAD TDP1 2162/4885L3MBTL1 858/4885CA1 1551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.